Clinical Trial Search

Primary: Percentage of Participants Alive Without Progression (Progression-free Survival) — 34.6; 43.1 percentage of participants — p=0.3436

Primary: Number of Participants With Treatment-emergent Adverse Events — 3; 4; 5; 5 Participants

Primary: Plasma Concentration of Brivaracetam (BRV) at Predose (<=1 Hour), Visit 3 — 149.0; NA; NA; 310.6 nanograms per milliliter (ng/mL)

Primary: Change From Baseline in Asthma Control Questionnaire (ACQ) Composite Scores to Week 12 — -0.427; -0.521; -0.512; -0.556 Score on a scale — p=0.5838

Primary: Difference in Z-score for Rank of Maximum Transverse Diameter (MTD) Regressed on Z-score at Baseline to Assess Growth in Abdominal Aortic Aneurysm MTD Determined by CT…

Primary: Percentage of Evaluable Participants Achieving Progression-Free Survival (PFS) at 3 Months — 81.8 percentage of participants

Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (SAEs) — 67; 5; 7; 0 Participants

Primary: Change in the Neuropsychiatric Inventory (NPI) Agitation/Aggression Domain Score From Day 1 (Stage 1 Baseline) to Day 36 (Stage 2 Baseline) and From Day 36 to Day 70…

Primary: Number of Subjects That Are Alive Without Respiratory Failure at Day 29. — 17; 14 Participants

Primary: Ocular Itching — 1.908; 1.925; 1.177; 2.758 units on a scale — p=0.0002

Primary: Incidence of Moderate to Severe Contact Dermatitis by SCORD Scoring — 16; 11 patients

Primary: Symptom Reduction — 26.02; 26.65 units on a scale*month

Primary: Change From Baseline in 24-hour Urine Protein to Creatinine Ratio (UPCR) — 0.326; 0.285; 0.305; 0.296 milligram/milligram (mg/mg) — p=0.9052

Primary: Incidence of Treatment Emergent Adverse Events (AEs) in Part 1 (Dose Escalation) — 0; 0; 0; 1 Participants

Primary: Part A: Danvatirsen With Durvalumab MTDs (Maximum Tolerated Dose) or Recommended Doses for Dose-expansion — 2; 3; 3; 2 mg/kg